COMMUNIQUÉS West-GlobeNewswire
-
Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026
14/07/2026 -
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026
14/07/2026 -
Seer Board of Directors Issues Letter to Shareholders Setting the Record Straight
14/07/2026 -
La Plata County continues to improve code revisions
14/07/2026 -
AVITA Medical to Announce Second Quarter 2026 Financial Results
14/07/2026 -
Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing
14/07/2026 -
Mobia Medical Announces Publication of Two-Year Data from VNS-REHAB Trial Demonstrating Durable and Continued Stroke Recovery with Vivistim® Paired VNS™ Therapy
14/07/2026 -
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer
14/07/2026 -
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
14/07/2026 -
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
14/07/2026 -
Kestra Medical Technologies Reports Fourth Quarter and Fiscal Year 2026 Financial Results
14/07/2026 -
Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
14/07/2026 -
DBV Technologies to Report Second Quarter 2026 Financial Results and Business Update on July 16, 2026
14/07/2026 -
PROCEPT BioRobotics® to Report Second Quarter 2026 Financial Results on August 4th, 2026
14/07/2026 -
Prenetics’ IM8 Secures $1 Billion Growth Financing from General Catalyst’s Customer Value Fund (CVF)
14/07/2026 -
Cosmos Health Share Buyback Expands to 4.49 Million Shares; Continues Open Market Repurchases
14/07/2026 -
Lanier Recovery Center earns BBB accreditation and A rating
14/07/2026 -
Applied Biologics Announces Successful Manufacture of First Research Construct for Disease-Modifying Osteoarthritis Gene Therapy Program
14/07/2026 -
AscellaHealth Named ACAP Preferred Vendor to Advance Specialty Pharmacy Strategy, Cost Containment and Care Management
14/07/2026
Pages